A clinical tool for predicting survival in ALS
- PMID: 27378085
- PMCID: PMC5136716
- DOI: 10.1136/jnnp-2015-312908
A clinical tool for predicting survival in ALS
Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a progressive and usually fatal neurodegenerative disease. Survival from diagnosis varies considerably. Several prognostic factors are known, including site of onset (bulbar or limb), age at symptom onset, delay from onset to diagnosis and the use of riluzole and non-invasive ventilation (NIV). Clinicians and patients would benefit from a practical way of using these factors to provide an individualised prognosis.
Methods: 575 consecutive patients with incident ALS from a population-based registry in South-East England register for ALS (SEALS) were studied. Their survival was modelled as a two-step process: the time from diagnosis to respiratory muscle involvement, followed by the time from respiratory involvement to death. The effects of predictor variables were assessed separately for each time interval.
Findings: Younger age at symptom onset, longer delay from onset to diagnosis and riluzole use were associated with slower progression to respiratory involvement, and NIV use was associated with lower mortality after respiratory involvement, each with a clinically significant effect size. Riluzole may have a greater effect in younger patients and those with longer delay to diagnosis. A patient's survival time has a roughly 50% chance of falling between half and twice the predicted median.
Interpretation: A simple and clinically applicable graphical method of predicting an individual patient's survival from diagnosis is presented. The model should be validated in an independent cohort, and extended to include other important prognostic factors.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Conflict of interest statement
PNL reports grants from MND Association Funding to support MND Clinic from 1995 to 2010, during the conduct of the study. CES reports consultancy and/or collaborative relationships with Glaxo Smith Kline, Vertex Pharmaceuticals, Chronos Therapeutics and Eli Lilly; he receives no personal gain and has never had any shares of any sort. AAC reports grants from EU FP7, grants from EU JPND—MRC and ESRC, grants from NIHR BRC in Mental Health and Dementia BRU, during the conduct of the study. All other authors declare no conflicts of interest.
Figures






Comment in
-
Clinical tool for predicting survival in ALS: do we need one?J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1275. doi: 10.1136/jnnp-2016-313683. Epub 2016 Jul 4. J Neurol Neurosurg Psychiatry. 2016. PMID: 27378084 No abstract available.
Similar articles
-
The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: a population based study in Modena, Italy.Amyotroph Lateral Scler Frontotemporal Degener. 2013 Sep;14(5-6):338-45. doi: 10.3109/21678421.2013.763281. Epub 2013 Feb 1. Amyotroph Lateral Scler Frontotemporal Degener. 2013. PMID: 23373475
-
Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort.BMJ Open. 2016 Sep 30;6(9):e012054. doi: 10.1136/bmjopen-2016-012054. BMJ Open. 2016. PMID: 27694488 Free PMC article.
-
Riluzole and other prognostic factors in ALS: a population-based registry study in Italy.J Neurol. 2018 Apr;265(4):817-827. doi: 10.1007/s00415-018-8778-y. Epub 2018 Feb 5. J Neurol. 2018. PMID: 29404735
-
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):191-206. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003. PMID: 13129806 Review.
-
[Amyotrophic lateral sclerosis].Ned Tijdschr Tandheelkd. 2010 Jul-Aug;117(7-8):380-2. doi: 10.5177/ntvt.2010.08.10122. Ned Tijdschr Tandheelkd. 2010. PMID: 20726497 Review. Dutch.
Cited by
-
The effectiveness of nonsteroidal anti-inflammatory drugs and acetaminophen in reduce the risk of amyotrophic lateral sclerosis? A meta-analysis.Sci Rep. 2020 Sep 8;10(1):14759. doi: 10.1038/s41598-020-71813-1. Sci Rep. 2020. PMID: 32901053 Free PMC article.
-
Home-Based Music Therapy to Support Bulbar and Respiratory Functions of Persons with Early and Mid-Stage Amyotrophic Lateral Sclerosis-Protocol and Results from a Feasibility Study.Brain Sci. 2022 Apr 13;12(4):494. doi: 10.3390/brainsci12040494. Brain Sci. 2022. PMID: 35448025 Free PMC article.
-
Utility of the ALSFRS-R for predicting ALS and comorbid disease neuropathology: The Veterans Affairs Biorepository Brain Bank.Muscle Nerve. 2022 Aug;66(2):167-174. doi: 10.1002/mus.27635. Epub 2022 Jun 4. Muscle Nerve. 2022. PMID: 35585776 Free PMC article.
-
Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease.J Neurol. 2020 Aug;267(8):2272-2280. doi: 10.1007/s00415-020-09838-9. Epub 2020 Apr 18. J Neurol. 2020. PMID: 32306171 Free PMC article.
-
Prognostic Factors and Epidemiology of Amyotrophic Lateral Sclerosis in Southeastern United States.Mayo Clin Proc Innov Qual Outcomes. 2024 Sep 17;8(5):482-492. doi: 10.1016/j.mayocpiqo.2024.07.008. eCollection 2024 Oct. Mayo Clin Proc Innov Qual Outcomes. 2024. PMID: 39323877 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous